'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds

The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip. 

Charity
Biotechs chasing cash to fund AMR projects • Source: Shutterstock

Biotechs are always battling for funding but the fight has become particularly fierce for the small and medium-sized enterprises (SMEs) which are trying to tackle the huge challenge that is antimicrobial resistance (AMR) poses.

Peter Jackson, executive director at the UK's AMR R&D Centre, is well placed to comment the struggles these smaller companies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category